In phase 2 studies of patients with ALK-rearranged NSCLC who were previously treated with alectinib, ceritinib resulted in an ORR of 25% and mPFS of 3.7 months12 and brigatinib resulted in an ORR of 34% and mPFS of 7.3 months.13 Here, ALK is linked to non-small cell lung carcinoma.